LXRX - NASDAQ
Lexicon Pharmaceuticals, Inc.
$1.85
-2.1%Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
At a Glance
Live SnapshotLexicon Pharmaceuticals, Inc. Management Team
Dr. Michael S. Exton Ph.D.
Chief Executive Officer & Director
Compensation
$830,545
Dr. Alan J. Main Ph.D.
Executive Vice President of Innovation & Chemical Sciences
Compensation
$595,452
Mr. Scott M. Coiante
Senior Vice President & Chief Financial Officer
Dr. Craig B. Granowitz M.D., Ph.D.
Senior Vice President & Chief Medical Officer
Compensation
$717,078
Ms. Lisa M. DeFrancesco
Senior Vice President of Investor Relations & Corporate Communications
Mr. Brian T. Crum
Senior Vice President, General Counsel & Secretary
Compensation
$616,116
Mr. Dixon Terry
Vice President of Compliance
Ms. Kristen L. Alexander
Vice President of Finance & Accounting
Compensation
$379,807
Ms. Carrie Siragusa
Vice President of Marketing
Ms. Desiree Gendron
Vice President of Sales & Training
Lexicon Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have purchased $2.72M worth of LXRX shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
2.1M
2.72M
0
0.00
+2.7M
+$2.72M
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Invus Global Management, Llc
Director, 10 Percent Owner:
$2.00M
Debbane Raymond
Director
$723K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $2.72M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
2 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
LXRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | March 16, 2026 | March 16, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 22, 2025 | April 22, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | March 26, 2024 | March 25, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | March 17, 2023 | March 16, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 08, 2022 | April 07, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | March 19, 2021 | March 19, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | March 13, 2020 | March 13, 2020 | 2020 | |
DEF 14A DEF 14A 2018 N/A | March 15, 2019 | December 31, 2018 | 2018 | |
DEF 14A DEF 14A 2018 N/A | March 16, 2018 | March 16, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | March 17, 2017 | March 17, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.